USGovernment-News.Com

USGovernment-News.Com

News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
Press release distribution service
Home : U.S. Government News Search Engine                          

Home > U.S. Government News > Marketplace :
Home: United State Government News
Home | News | Submit Press Release |

VFC's Stock House Stock Watch Wednesday, 6 March 2013

(USGovernment-News.Com, March 06, 2013 ) New York, NY -- A new DOW record is in the books and world stocks were moving higher on Wednesday as a result. As mentioned earlier this week, we're at a serious pivot point now as to whether the markets can sustain these or whether a pullback will materialize based on the developments of other general conditions and geopolitical events.



VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies multiple stocks, stories and investing ideas to consider for the day, Wednesday, 6 March. This is an abbreviated report. A full examination of Wednesday's hot stocks to watch is available by visiting VFC's Stock House at: http://VFCsStockHouse.com



A positive private jobs report on Wednesday AM was key in determining the strength of the new record over the short term, but investors will now look towards the effects of sequestration and how budget cuts can have an impact over the coming weeks.



Most of the expected cuts that were regarded as a doomsday scenario by many politicians leading into the March 1 deadline, however, are not due to be implemented until the April time frame, according to the most recent reports from Washington. That allows more time for our elected officials to come up with something solid in terms of a budget for the first time in years, but it also leaves us in a position where investors could feel complacent with the bullish momentum just before the real impact could be seen. Many government programs are slated to lose at least portions of their funding and - maybe even more important for the already sluggish recovery - federally paid workers could be in for a slate of pay cuts and furloughs. Those cuts could offer the markets a look at the potential impacts of having an increasing portion of the population relying on government money, whether it be through government jobs or handouts...



As always, there will be plenty of individual stocks and stories to keep an eye on while the major news plays out. Here are just a few of them for Wednesday, 6 March 2013...



Explosive Trace Detection (ETD) / Global Defense:



Implant Could Potentially Be Impacted By DC's Stalled Budget Talks



In discussing the potential effects of sequestration and Washington's stalled budget talks, it may be worthwhile to consider the potential Impacts that these issues could have on Implant Sciences (IMSC) and other companies that may be looking towards government money to fuel growth. In the case of Implant, investors had speculated that recent TSA approval of its Quantum Sniffer B220 explosive trace detector would result in the landing of some key deals potentially associated with Washington's anti-terrorism efforts in relation to air cargo and overall aircraft and airline security. While the potential remains for Implant to land deals in the private sector for air cargo providers, the company's potential to enter into the government sector could be stalled by the budget woes in Washington, and investors should take note of that fact.



As news trickles out from DC regarding spending cuts and furloughs, one item mentioned is that Washington is in a period now where money already obligated to existing contracts will not be effected, but any new contracts or requests for fiscal obligations will be just as stalled as an elected official's 'to do' list once they arrive for work post-election. That could impact the type of new money that would be necessary for Implant to secure the government contracts - that's another aspect to consider in the patience game.



Such a scenario could lead to a period where investors may grow anxious at a point when large government-related deals were anticipated, but those looking towards the long term may appreciate the recent price pullback as an opportune time to add or continue with accumulation. As previously discussed, the advantages of Implant's ETD technology over the competition are distinct, and that underlies the potential for the company to play a large role in the growing homeland defense market. For that to occur, though, homeland defense needs to be funded and as we all know, the Mets might win the 'outfield of the year' award before a budget gets passed in DC.



A slowdown in domestic growth does not mean that the company can't come through on the international market, as has been noted in the past. On Tuesday, too, Implant noted that an existing aviation security customer in Africa had purchased three QS-H150 handheld units as part of a follow-on order. Having demonstrated a significant amount of overseas growth over the past year, including a multi-million dollar order to India, this company is not overly-reliant on the US market right now - but a budget resolution could help, as it'll free up new money for contracts again.



Also take note of the credit extension with DMRJ that places the company on stable financial grounding, at least for the next year.



Technology:



BlackBerry Sinks As Market Soars



Global markets may be setting multi-year highs these days, but shares of BlackBerry (BBRY) have retreated off their recent highs and were down another near-two percent on Tuesday. Speculation is still rampant about just how successful the launch of the new BlackBerry 10 platform is going, but most are reserving judgement until the full US launch is underway. Many consumer reviews have been positive thus far and the instant overseas statistics are encouraging, although there is some concern that abundant inventories and pricing promotions - both of which could lead to revenue reductions - may eat into margins.



The recent decline in the BBRY share price should not be attributed fully to expectations of a weak launch. As the market has inched higher just about every day over the past couple of weeks - culminating in Tuesday's triple-digit rally to break the record high - many investors have been concentrating their cash towards the hot DOW players and other market movers to enjoy the bull ride. As they say, everyone makes money in the bull market, so many investors tend to concentrate cash into those more stable investments that are likely to ride the broad-market wave. BlackBerry, still being highly speculative until those de-facto sales numbers start rolling in, doesn't quite fit that bill as it's still a potential rebound and recovery story, not necessarily a 'trade in-line with the market' play...



Healthcare, Biotech, Pharmaceutical:



AEterna Zentaris Could Rise Even In Market Pulls Back



AEterna Zentaris (AEZS) is another more speculative play that has slipped lower recently but could rise even if the market decides to pull back from its record highs, mainly due to catalysts that are still to unfold over the coming weeks and months. Another reason that AEZS could trade independently of the broad market action, if news and developments warrant, is for the same reasons discussed in the BlackBerry discussion above. As investors pull profits from the highs of this record-setting rally, then money could flow back into those investments more speculative in nature that have the potential to spike - even in a down market - based on unfolding catalysts.



As previously identified, one potential near-term catalyst for AEterna is the expected NDA filing for AEZS-130 as a diagnostic test for Adult Growth Hormone Deficiency. This product candidate is not quite expected to become a huge money maker, if only because of the relative size of the intended market, but AEterna maintains world-wide rights to and - if approved - could provide a future revenue stream to assist in funding other pipeline products.



Also watch for developments on the AEZS-108 front. AEterna recently announced that the first patient had been treated in a Phase II trial testing AEZS-108 in the treatment of triple-negative breast cancer, but Phase II studies also continue for AEZS-108 the treatment of prostate and bladder cancers. Interim results from these trials are expected at various points throughout 2013. AEZS-108 is also being prepared for a near-term launch of a Phase III trial in the indication of endometrial cancer, according to the latest information published to the company's website, after already having established a proven record of success in other early to mid-stage trials. Investors looking for a place to insert some speculative money following the broad-market run, may like what the see on the AEZS catalyst plate...



Roundup: Judging by international market action and Wednesday's encouraging private jobs data, we're likely to see new record highs during the course of the day. As mentioned above, though, it's not the time to get complacent as the global recovery is hardly set in stone and there are still many speed bumps that can materialize along the way, especially in the absence of resolution in Washington. While enjoying the broad market run that has filled up those 401Ks again, now's the time to start looking for the individual stocks and stories that have the potential to move higher based on catalysts and development, even if a pullback occurs.



Happy Trading!!!



Disclosure: Long IMSC, AEZS.



Follow the developments of these and other small cap stocks at VFCsStockHouse.com



Contact VFC's Stock House: vfc@vfcsstockhouse.com



Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse



'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



About VFCsStockHouse.com: VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.



For full disclaimer visit: http://vfcsstockhouse.com





VFC's Stock House

VFC

240-786-2111

vfc@vfcsstockhouse.com

Source: EmailWire.Com

Source: EmailWire.com

U.S. Governement News: Politics
  • Presidential Elections
  • Democrates
  • Congress
  • House of Representatives
  • President Obama
  • Republican Party
  • Mitt Romney
  • U.S. Senate
  • U.S. Military
  • U.S. Politics
  • Politics Video Feeds

    U.S. Government Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    Governing
    Point of Beginning
    Overall Labor Effectiveness (OLE) Achieving a Highly Effective Workforce

    No credit cards, coupons, or promo codes required. Try it today!

    USGovernment-News.Com is a news service of GroupWeb Media LLC